A Clinical Phase I / II Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer.

Trial Profile

A Clinical Phase I / II Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2015

At a glance

  • Drugs Belinostat (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Dec 2010 First patient dosed, according to a Spectrum Pharmaceuticals media release.
    • 29 Dec 2010 Planned number of patients changed from 58 to 35, according to a TopoTarget media release.
    • 29 Dec 2010 First patient enrolled, according to a TopoTarget media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top